S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Teva Pharma is the way to play the re-rise of generic drugs
3 reasons a squeeze could be in Paramount's coming attractions
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
BellRing Brands gets pumped on the Ozempic weight-loss trend
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Teva Pharma is the way to play the re-rise of generic drugs
3 reasons a squeeze could be in Paramount's coming attractions
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
BellRing Brands gets pumped on the Ozempic weight-loss trend
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Teva Pharma is the way to play the re-rise of generic drugs
3 reasons a squeeze could be in Paramount's coming attractions
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
BellRing Brands gets pumped on the Ozempic weight-loss trend
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Teva Pharma is the way to play the re-rise of generic drugs
3 reasons a squeeze could be in Paramount's coming attractions
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
BellRing Brands gets pumped on the Ozempic weight-loss trend

Bellicum Pharmaceuticals (BLCM) Competitors

$0.23
+0.04 (+21.51%)
(As of 11/27/2023 ET)
Compare
Today's Range
$0.19
$0.23
50-Day Range
$0.10
$0.48
52-Week Range
$0.06
$1.50
Volume
8,546 shs
Average Volume
18,646 shs
Market Capitalization
$2.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BLCM vs. INM, ALLR, ONCR, HSTO, CPHI, CMND, EVFM, ADTX, SCPS, and PXMD

Should you be buying Bellicum Pharmaceuticals stock or one of its competitors? The main competitors of Bellicum Pharmaceuticals include InMed Pharmaceuticals (INM), Allarity Therapeutics (ALLR), Oncorus (ONCR), Histogen (HSTO), China Pharma (CPHI), Clearmind Medicine (CMND), Evofem Biosciences (EVFM), Aditxt (ADTX), Scopus BioPharma (SCPS), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical preparations" industry.

Bellicum Pharmaceuticals vs.

InMed Pharmaceuticals (NASDAQ:INM) and Bellicum Pharmaceuticals (NASDAQ:BLCM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings, community ranking and dividends.

0.5% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 4.9% of Bellicum Pharmaceuticals shares are held by institutional investors. 1.4% of InMed Pharmaceuticals shares are held by insiders. Comparatively, 10.3% of Bellicum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

InMed Pharmaceuticals currently has a consensus price target of $45.00, suggesting a potential upside of 11,757.71%. Given Bellicum Pharmaceuticals' higher probable upside, equities research analysts plainly believe InMed Pharmaceuticals is more favorable than Bellicum Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InMed Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Bellicum Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Bellicum Pharmaceuticals received 350 more outperform votes than InMed Pharmaceuticals when rated by MarketBeat users. Likewise, 59.97% of users gave Bellicum Pharmaceuticals an outperform vote while only 47.06% of users gave InMed Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
InMed PharmaceuticalsOutperform Votes
8
47.06%
Underperform Votes
9
52.94%
Bellicum PharmaceuticalsOutperform Votes
358
59.97%
Underperform Votes
239
40.03%

InMed Pharmaceuticals has a beta of -0.07, suggesting that its stock price is 107% less volatile than the S&P 500. Comparatively, Bellicum Pharmaceuticals has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.

Bellicum Pharmaceuticals has a net margin of 0.00% compared to Bellicum Pharmaceuticals' net margin of -147.87%. Bellicum Pharmaceuticals' return on equity of -57.65% beat InMed Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
InMed Pharmaceuticals-147.87% -57.65% -49.23%
Bellicum Pharmaceuticals N/A -753.03%-157.93%

In the previous week, InMed Pharmaceuticals and InMed Pharmaceuticals both had 1 articles in the media. InMed Pharmaceuticals' average media sentiment score of 0.69 beat Bellicum Pharmaceuticals' score of 0.00 indicating that Bellicum Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
InMed Pharmaceuticals Neutral
Bellicum Pharmaceuticals Positive

InMed Pharmaceuticals has higher revenue and earnings than Bellicum Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InMed Pharmaceuticals$4.14M0.48-$7.95MN/AN/A
Bellicum Pharmaceuticals$1.50M1.43-$24.97MN/AN/A

Summary

Bellicum Pharmaceuticals beats InMed Pharmaceuticals on 8 of the 13 factors compared between the two stocks.


Get Bellicum Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLCM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BLCM vs. The Competition

MetricBellicum PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.15M$5.67B$4.40B$6.69B
Dividend YieldN/A3.05%3.00%20.29%
P/E RatioN/A13.23116.3013.55
Price / Sales1.43701.852,674.67156.23
Price / CashN/A16.1021.5722.84
Price / Book0.983.963.814.49
Net Income-$24.97M$198.30M$121.63M$176.13M
7 Day Performance68.66%5.13%2.88%2.08%
1 Month Performance25.56%9.64%13.29%9.44%
1 Year Performance-78.27%4.33%5.10%2.53%

Bellicum Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INM
InMed Pharmaceuticals
1.1389 of 5 stars
$0.38
-5.0%
$45.00
+11,739.0%
-86.7%$1.27M$4.72M0.0013Gap Down
ALLR
Allarity Therapeutics
0 of 5 stars
$0.51
+2.0%
N/A-99.9%$1.39MN/A0.0014Positive News
Gap Down
ONCR
Oncorus
0 of 5 stars
$0.04
+87.0%
$2.00
+4,551.2%
-96.8%$1.12MN/A-0.0164
HSTO
Histogen
0 of 5 stars
$0.34
flat
N/A-68.7%$1.45M$19,000.00-0.127
CPHI
China Pharma
0 of 5 stars
$0.09
flat
N/AN/A$1.05M$7.78M0.00234Analyst Report
Gap Down
CMND
Clearmind Medicine
0 of 5 stars
$0.12
flat
N/A-97.8%$844,000.00N/A0.00N/AStock Split
News Coverage
Gap Down
EVFM
Evofem Biosciences
0 of 5 stars
$0.07
flat
N/A-99.3%$834,000.00$11.39M0.0035
ADTX
Aditxt
2.0984 of 5 stars
$3.46
-3.1%
$61.00
+1,663.0%
-95.0%$827,000.00$948,114.000.0061
SCPS
Scopus BioPharma
0 of 5 stars
$0.04
flat
N/A-70.5%$1.73MN/A0.0013High Trading Volume
PXMD
PaxMedica
1.4958 of 5 stars
$0.80
-18.4%
N/A-97.2%$773,000.00N/A-0.033Positive News
Gap Down
High Trading Volume

Related Companies and Tools

This page (NASDAQ:BLCM) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -